Latent TGF beta 1/TGFB1, His, Human
Latent TGF Beta 1/TGFB1, His, Human

Immobilized Latent TGF beta 1/TGFB1, His, Human, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ITGAV&ITGB6, His-Avi Tag with the EC50 of 2.1μg/ml determined by ELISA.

Latent TGF Beta 1/TGFB1, His, Human

Immobilized Latent TGF beta 1/TGFB1, His, Human, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ITGAV&ITGB8, His Tag with the EC50 of 9.62μg/ml determined by ELISA.

Latent TGF Beta 1/TGFB1, His, Human

Immobilized Latent TGF beta 1/TGFB1, His, Human at 0.5μg/ml(100μl/well) on the plate. Dose response curve for Human TGF-Beta RII, hFc Tag with the EC50 of 0.22μg/ml determined by ELISA.

Latent TGF Beta 1/TGFB1, His, Human

Latent TGF beta 1/TGFB1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Latent TGF beta 1/TGFB1, His, Human

Latent TGF beta 1 cDNA encodes a 390 amino acid precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin‑like convertase processes the proprotein to generate an N‑terminal 249 aa latency‑associated peptide (LAP) and a C‑terminal 112 aa mature TGF‑ beta 1. Disulfide‑linked homodimers of LAP and TGF‑ beta 1 remain non‑covalently associated after secretion, forming the small latent TGF‑ beta 1 complex.
Z05565
¥95,137.00

Ask us a question
Product Introduction
Species Human
Protein Construction
His Latent TGF beta 1/TGFB1 [Leu30-Ser390 (C33S)]
Accession # P01137
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa (LAP) / 13-15 kDa (Mature TGF Beta 1) based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Latent TGF Beta 1/TGFB1, His, Human
    • Latent TGF Beta 1/TGFB1, His, Human

    Immobilized Latent TGF beta 1/TGFB1, His, Human, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ITGAV&ITGB6, His-Avi Tag with the EC50 of 2.1μg/ml determined by ELISA.

  • Latent TGF Beta 1/TGFB1, His, Human
    • Latent TGF Beta 1/TGFB1, His, Human

    Immobilized Latent TGF beta 1/TGFB1, His, Human, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ITGAV&ITGB8, His Tag with the EC50 of 9.62μg/ml determined by ELISA.

  • Latent TGF Beta 1/TGFB1, His, Human
    • Latent TGF Beta 1/TGFB1, His, Human

    Immobilized Latent TGF beta 1/TGFB1, His, Human at 0.5μg/ml(100μl/well) on the plate. Dose response curve for Human TGF-Beta RII, hFc Tag with the EC50 of 0.22μg/ml determined by ELISA.

  • Latent TGF Beta 1/TGFB1, His, Human
    • Latent TGF Beta 1/TGFB1, His, Human

    Latent TGF beta 1/TGFB1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Latent TGF beta 1 cDNA encodes a 390 amino acid precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin‑like convertase processes the proprotein to generate an N‑terminal 249 aa latency‑associated peptide (LAP) and a C‑terminal 112 aa mature TGF‑ beta 1. Disulfide‑linked homodimers of LAP and TGF‑ beta 1 remain non‑covalently associated after secretion, forming the small latent TGF‑ beta 1 complex.
Synonyms CEDLAP; DPD1; TGF beta1; TGFB; TGFB1; TGFbeta; TGF-beta-1; TGF β1; TGFβ; TGF-β-1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.